drugset / Trial / NCT04179474
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
RandomizedParallel-groupOpen-labelBasic science
Summary
This study will evaluate the potential for a pharmacokinetic (PK) interaction and provide safety and tolerability information when ubrogepant and erenumab or ubrogepant and galcanezumab are co-administered.
Timeline
- Start
- 2019-09-26
- Primary completion
- 2019-12-23
- Completion
- 2019-12-23
Publications
- Results Jakate A,Boinpally R, Butler M, Borbridge L, Contreras-De Lama J, McGeeney D, Periclou A. Safety and tolerability of ubrogepant for the acute treatment of migraine following co-administration with preventive monoclonal antibody treatment [abstract]. In:62nd Annual Scientific Meeting American Headache Society; June2020; San Diego, California.
- Boinpally RR, Trugman JM. Ubrogepant Plasma and Cerebrospinal Fluid Exposures in Participants With a History of Migraine: Findings From a Phase 1b Open-Label Trial. Clin Transl Sci. 2026 Apr;19(4):e70560. doi: 10.1111/cts.70560.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erenumab | Monoclonal antibody | 140 mg | Subcutaneous |
| Subject | Galcanezumab | Monoclonal antibody | 120 mg | Subcutaneous |
| Subject | Ubrogepant | Small molecule | 100 mg | Oral |